SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...

The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the biotech CureVac.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GSK, also known as GlaxoSmithKline, filed the suit in a Delaware federal court on Thursday, alleging that Pfizer and BioNTech's Comirnaty vaccines infringe upon vaccine technology developed by GSK ...

The deal also now includes exclusive rights for China's largest vaccine company to explore a collaboration on GSK's (GSK.L), opens new tab respiratory syncytial virus (RSV) vaccine, Arexvy, in China, ...

One example of this is GSK’s commitment to make its new malaria vaccine RTS,S affordable, the company planning to price it at £8.50 (10.42 US dollars) per child, based on demand of around 100 ...

GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products (Zhifei), China's largest vaccine maker, to co-market its shingles vaccine Shingrix in ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...